Ovarian cancer development and metastasis

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1053-1064

  Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL RECEPTOR; INTEGRIN; PROTEINASE;

ANOIKIS; ASCITES; CACHEXIA; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; CHEMOSENSITIVITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTESTINE OBSTRUCTION; MESOTHELIUM; METASTASIS; NONHUMAN; OMENTUM; OVARY CARCINOMA; PERITONEAL CAVITY; PERITONEAL FLUID; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; RECEPTOR BINDING; REVIEW; TUMOR DIFFERENTIATION; UTERINE TUBE;

EID: 77956495728     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100105     Document Type: Review

References (101)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249
2. Eisenkop S, Spirtos NM: The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 2001, 82:143-149 (Pubitemid 32634967)
3. Bristow RE, del Carmen M, Kaufman H, Montz FJ: Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003, 197:565-574 (Pubitemid 38223841)
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259
5. Winter WE, Maxwell L, Tian C, Carlson JW, Ozols RF, Rose P, Markmann M, Armstrong DK, Muggia F, McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007, 25:3621-3627 (Pubitemid 47372600)
6. Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 353:34-43 (Pubitemid 43048949)
7. Tavassoli FA and Devilee P: Tumors of the ovary and peritoneum. Tumors of the Breast and Female Genital Organs. Edited by P Kleihues and L Sobin. Lyon, France, IARC Press, 2003, pp. 113-203
8. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuk A, Whitaker R, Gershenson D, Mills GB, Bast RC, Lu K: Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005, 11:6116-6126 (Pubitemid 41262937)
9. Fathalla M: Factors in the causation and incidence of ovarian cancer. Obstetr Gynecol Survey 1972, 27:751-768
10. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin Oncol 1998, 25:281-304
11. Cheng W, Liu J, Yoshida H, Rosen D, Naora H: Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2008, 11:531-537 (Pubitemid 40685976)
12. Naora H: Developmental patterning in the wrong context: the paradox of epithelial ovarian cancer. Cell Cycle 2005, 4:1033-1035
13. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH: Diagnostic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001, 195:451-456 (Pubitemid 33069670)
14. Powell B, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J: Risk-reducing salpingo-ophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005, 23:127-132 (Pubitemid 41702631)
15. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007, 31:161-169 (Pubitemid 46175016)
16. Folkins AK, Jarboe EA, Roh MH, Crum CP: Precursor to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 2009, 113:391-396
17. Dubeau L: The cell of origin of ovarian epithelial tumors. Lancet Oncol 2008, 9:1191-1197
18. Auersperg N, Woo MMM, Gilks CB: The origin of ovarian carcinomas: a developmental view. Gynecol Oncol 2008, 110:452-454
19. Kurman R, Shih I-M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443
20. Singer G, Oldt R, Cohen Y, Wang B, Sidransky D, Kurman R, Shih I-M: Mutations in B-raf and K-ras characterize the development of low-grade ovarion serous carcinoma. J Natl Cancer Inst 2003, 95:484-486 (Pubitemid 36432423)
21. Shih I-M, Kurman R: Ovarian tumorigenesis: a proposed model based on morpholgical and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518
22. Gershenson D, Sun CC, Lu K, Coleman RL, Sood AK, Malpica A, Deavers M, Silva EG, Bodurka-Bevers D: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006, 108:361-368 (Pubitemid 44305678)
23. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170
24. Hsu C-Y, Bristow RE, Cha MS, Wang B, Ho CL, Kurman R, Wang TL, Shih I-M: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004, 10:6432-6436 (Pubitemid 39346537)
25. Prowse A, Manek S, Varma R, Liu J, Godwin AK, Maher E, Tomlinson I, Kennedy S: Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006, 1189:556-562 (Pubitemid 43955708)
26. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D: The molecular signature of endometriosis-associated endometroid ovarian cancer differs significantly from endometriosis-independent endometroid ovarian cancer. Fertil Steril 2009, doi: 10.1016/j.fertnstert.2009.06.039
27. Dinulescu D, Ince T, Quade B, Shafer S, Crowley D, Jacks T: Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarin cancer. Nat Med 2005, 11:63-70 (Pubitemid 40215839)
28. Romero I, Gordon I, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu D, Krausz T, Kim H, Gilliam M, Lengyel E: Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res 2009, 2:792-799
29. Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009, 6:1-11
30. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman R, Shih I-M, Wang TL: Analysis of DNA copy number alterations in ovarian serous tumors identified new molecular genetic changes in low-grade and high-grade carcnomas. Cancer Res 2009, 69:4036-4042
31. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z: High resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2009, 2:21
32. Flesken-Nikitin A, Choi K, Eng JP, Shmidt EN, Nikitin A: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63:3459-3463 (Pubitemid 36793020)
33. Kohler MF, Marks JR, Wiseman R, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuk A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993, 85:1513-1519 (Pubitemid 23269187)
34. Singer G, Stöhr R, Cope L, Dehari R, Hartman A, Cao DF, Wang TL, Kurman R, Shih I-M: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29:218-224 (Pubitemid 40170640)
35. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE, Haites NE: p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993, 53:2128-2132
36. Zeimet AG, Marth C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003, 4:415-419
37. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa J: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarain carcinomas. Proc Natl Acad Sci USA 1992, 89:9267-9271
38. Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray J: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102 (Pubitemid 29036292)
39. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon DJ, Velculescu V, Kurman R, Shih I-M: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009, 174:1597-1601
40. Gupta G, Massague J: Cancer metastasis: building a framework. Cell 2006, 127:679-695
41. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B: Mechanism of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984, 44:3584-3592 (Pubitemid 14098615)
42. Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2006, 17:548-558
43. Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and IG-cams in cancer. Nat Rev 2004, 4:118-132 (Pubitemid 38198740)
44. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1429
45. Veatch AL, Carson LF, Ramakrishnan S: Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 1994, 58:393-399
46. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F: Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 1997, 28:922-928 (Pubitemid 27355552)
47. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643
48. Ahmed N, Thompson EW, Quinn MA: Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007, 213:581-588 (Pubitemid 350058249)
49. Hudson LG, Zeineldin R, Stack MS: Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008, 25:643-655
50. Patel IS, Madan P, Getsios S, Bertrand M, MacCalman C: Cadherin switching in ovarian cancer progression. Int J Cancer 2003, 106:172-177 (Pubitemid 36835168)
51. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, Konishi I: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003, 163:1437-1447 (Pubitemid 37175091)
52. Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG, Stack MS: Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007, 67:2030-2039 (Pubitemid 46424220)
53. Burleson KM, Hansen LK, Skubitz AP: Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis 2004, 21:685-697
54. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E: C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007, 67:1670-1680 (Pubitemid 46383393)
55. Cannistra SA: Cancer of the ovary. N Engl J Med 2004, 351:2519-2529
56. Byrne A, Ross L, Holash J, Nakanishi M, Hu L, Yancopoulos G, Jaffe RB: Vascular endothelial growth factor-Trap decreases tumor burden, inhibits ascites, and causes dramtic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728 (Pubitemid 37499496)
57. Hu L, Hofman J, Holash J, Yancopoulos G, Sood AK, Jaffe RB: Vascular endothelial growth factor Trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6972 (Pubitemid 41428755)
58. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Skubitz AP: Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004, 93:170-181
59. 1-Integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 2007, 6:11
60. 1-Integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001, 159:2071-2080
61. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p metastatic dissemination. Cancer Res 2009, 69:7121-7129
62. Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz, Bryne M, Risberg B, Kristensen G, Trope C, Kopolovic J, Reich R: Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusion. Am J Clin Pathol 2001, 115:517-524
63. 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular spheroids. Cancer Res 1997, 57:2388-2393
64. Green SK, Francia G, Isidoro C, Kerbel RS: Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-159 (Pubitemid 39193689)
65. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Lichtenegger W, Gülten OÖ: Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 2009, 99:424-427
66. Daya D, McCaughy WT: Pathology of the peritoneum: a review of selected topics. Semin Diagn Pathol 1991, 8:277-289
67. Kenny HA, Krausz T, Yamada SD, Lengyel E: Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer 2007, 121:1463-1472 (Pubitemid 47328704)
68. Witz CA, Montoya-Rodriguez I, Cho S, Centonze V, Bonewald L, Schenken RS: Composition of the extracellular matrix of the peritoneum. J Soc Gynecol Investig 2001, 8:299-304
69. Kenny HA, Dogan S, Zillhardt M, Mitra AK, Yamada SD, Krausz T, Lengyel E: Organotypic models of metastasis: a three dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Ovarian Cancer. Edited by MS Stack and DA Fishman. New York, Springer, 2009, pp. 335-351
70. Kenny HA, Kaur S, Coussens L, Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008, 118:1367-1379 (Pubitemid 351500430)
71. 1-Integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999, 73:362-367
72. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 2009, 33:49-54
73. 3 integrins in ovarian cancer. Gynecol Oncol 1995, 58:216-225
74. 3 mediates up-regulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int J Biochem Cell Biol 2008, 40:2746-2761
75. 3-Integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009, 175:2184-2196
76. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993, 53:3830-3838 (Pubitemid 23252051)
77. Strobel T, Swanson L, Cannistra SA: In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD 44 in the process of peritoneal implantation. Cancer Res 1997, 57:1228-1232
78. Kenny HA, Lengyel E: MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009, 8:683-688
79. Huang S, Van Arsdall M, Tedjarti S, McCarthy M, Wu W, Langley R, Fidler IJ: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002, 94:1134-1142 (Pubitemid 34919050)
80. Heath R, Jayne D, O'Leary R, Morrison E, Guillou P: Tumor-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004, 90:1437-1442 (Pubitemid 38586274)
81. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero I, Lengyel E, Peter ME: CD95/Fas promotes tumor growth. Nature 2010, 465(7297):492-496
82. Moser TL, Pizzo SV, Bafetti L, Fishman DA, Stack MS: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin. Int J Cancer 1996, 67:695-701 (Pubitemid 26300989)
83. Hwang JE, Mangala LS, Fok JY, Lin YG, Merritt W, Spannuth W, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers M, Coleman RL, Lopez- Berestein G, Mehta K, Sood AK: Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5849-5858
84. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D: Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007, 67:7194-7202 (Pubitemid 47206547)
85. Satpathy M, Shao M, Emerson R, Donner DB, Matei D: Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem 2009, 284:15390-15399
86. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D: Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 2009, 69:9192-9201
87. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101:1364-1374 (Pubitemid 39180392)
88. Spannuth W, Nick AM, Jennings N, Armaiz-Pena G, Mangala L, Danes CG, Lin Y, Merritt W, Thaker P, Kamar A, Han L, Tonra JR, Coleman RL, Ellis LM, Sood AK: Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009, 124:1045-1053
89. Sher I, Adham SA, Petrik J, Coomber BL: Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009, 124:553-561
90. Garcia A, Hirte H, Fleming G, Yang D, Tsao-wei D, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza A: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the california, chicago, and princess hospital phase II consortia. J Clin Oncol 2008, 26:76-82
91. Jacobs IJ, Kohler MF, Wiseman R, Marks JR, Whitaker R, Kerns BAJ, Humphrey P, Berchuk A, Ponder BAJ, Bast RC: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992, 84:1793-1798
92. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR, Thiele J, Grindle SM, Bliss RL, Skubitz AP: Differential gene expression in ovarian carcinoma. Am J Pathol 2004, 165:397-414
93. Adib T, Henderson S, Perrett C, Bourmpoulia D, Lederman J, Boshoff C: Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004, 90:686-692 (Pubitemid 38297211)
94. Israeli O, Gotlieb WH, Friedman E, Korach J, Friedman E, Goldman B, Zeltser A, Ben-Baruch G, Rienstein S, Aviram-Goldring A: Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet Cytogenet 2004, 154:16-21 (Pubitemid 39286167)
95. Khalique L, Ayhan A, Whittaker JC, Singh N, Jacobs IJ, Gayther SA, Ramus SJ: The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer 2009, 124:1579-1586
96. Ramawamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54 (Pubitemid 36068681)
97. Jones S, Chen W-D, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu V, Kinzler KW, Vogelstein B, Willis J, Markowitz S: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008, 105:4283-4288 (Pubitemid 351754372)
98. Burger RA: A new model of ovarian carcinogenesis may influence early detection strategies. Am J Obstet Gynecol 2008, 198:349-350
99. Kurman R, Visvanathan K, Roden R, Wu TC, Shih I-M: Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008, 351-356 (Pubitemid 351451941)
100. Bapat SA, Mali AM, Koppikar CB, Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029
101. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu D, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe P: Ovarian cancer side populations defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006, 103:11154-11159 (Pubitemid 44156488)